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Incarceration, drug use, and infectious diseases: a syndemic 
still not addressed
Substantial progress has been made in reducing HIV 
and, to a lesser extent, hepatitis C virus (HCV) incidence 
among people who inject drugs (PWID) globally.1 
However, specific populations of PWID, particularly 
those who are incarcerated, are often overlooked or left 
out of interventions designed to reduce HIV and HCV 
transmission. In particular, we know that the period 
immediately following release from incarceration is a 
time of very high risk for HIV and HCV transmission as 
well as opioid-related overdose, largely owing to relapse 
to drug use post-release.2–4 In their systematic review 
and meta-analysis in The Lancet Infectious Diseases, 
Jack Stone and colleagues5 clearly reinforce this point 
by quantitatively synthesising data across studies to 
show that recent incarceration (past 3, 6, or 12 months, 
or since last follow-up visit) is strongly correlated with 
HIV and HCV acquisition risk. Recent incarceration was 
associated with an 81% increase in HIV acquisition 
risk (RR 1·81; 95% CI 1·40–2·34; p<0·001) and with a 
62% increase in HCV acquisition risk (RR 1·62; 95% CI 
1·28–2·05; p<0·001).
There is a large body of evidence supporting the 
effectiveness of harm-reduction strategies, such 
as syringe exchange programmes and medication-
assisted treatment, yet the implementation of these 
strategies is highly variable globally and they are often 
not available in criminal justice settings.6–8 Although 
the hypothesised link between incarceration and HIV 
and HCV acquisition among PWID has historically had 
a singular focus on relapse to drug use in the period 
immediately following release, Stone and colleagues 
point out some other crucial, related factors that must 
be considered. Although not statistically significant, the 
authors found an attenuated risk for HCV acquisition 
when controlling for recent homelessness, suggesting 
that housing instability might be an important 
determinant in HCV transmission. Although Stone and 
colleagues do not explicitly assess other potential social 
or structural determinants in their review, they point out 
that incarceration is associated with numerous social 
determinants including poverty, unemployment, and, 
as previously stated, homelessness.9,10 This review, along 
with existing evidence, suggests that incarceration 
itself might be more appropriately viewed as a social 
or structural determinant of health and might exert 
synergistic effects with other, more traditionally 
conceived determinants such as poverty, housing, 
employment, and social support.9,10 Viewed in this 
way, incarceration has its own effect on health-related 
outcomes and exacerbates the adverse effects of other 
well-known social determinants of health, which are all 
correlated with substance use and risk factors related 
to HIV and HCV. To lessen this effect, countries with 
high prevalences of incarceration should rely less on 
law enforcement solutions to drug use and, instead, 
turn to a public health-oriented approach or, at the very 
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least, incorporate prevention-oriented approaches into 
existing law enforcement strategies.
Research by others has shown that access to 
medication-assisted treatment, both in correctional 
settings and in the community post-release, can lessen 
risk of HIV and HCV infection (and other adverse health 
outcomes) and also decrease the risk of being re-
incarcerated in the future.6,7 Finally, while these findings 
add important evidence of the effect of incarceration 
on HIV and HCV acquisition risk, much more nuanced 
information related to incarceration is needed to more 
clearly understand where and whom to target for future 
interventions. As the authors point out, many HIV and 
HCV-related studies do not measure incarceration, and 
when they do, the type of incarceration (jail vs prison, 
whereby jail refers to short-term incarceration, typically 
less than a year, before sentencing and prison refers to 
longer term incarceration after sentencing has been 
rendered) and length of sentence are not recorded. In 
addition, more longitudinal research that assesses the 
effect of repeated incarceration is necessary.
The healthiest communities are often among the 
safest communities. Thus, harm reduction strategies 
to reduce infectious disease transmission among PWID 
keeps communities (both drug-using communities and 
non-drug using communities alike, as infectious agents 
do not respect socioeconomic or cultural boundaries) 
both healthier and safer. By contrast, incarcerating 
PWID, as suggested by data presented here by Stone 
and colleagues, leads to unhealthy outcomes and 
exacerbated risk. By limiting access to treatment, 
we risk jeopardising the health and safety of entire 
communities because the social and structural factors 
that lead to crime and poor health, including infectious 
disease, are often overlapping.
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When is contact tracing not enough to stop an outbreak?
Because of the security situation in the eastern region 
of the Democratic Republic of the Congo, teams 
responding to the ongoing Ebola virus outbreak cannot 
access some communities, making reliable contact 
tracing difficult.1
Despite the fanfare given to vaccines and other 
innovations, contact tracing remains a staple of 
outbreak control.2 Although few studies have formally 
evaluated how well contact tracing works, the recent 
containment of the Ebola virus in the Democratic 
Republic of the Congo’s Equateur Province, Nipah virus 
in India, as well as the numerous other outbreaks halted 
each year, suggest that contact tracing is effective 
when transmission is localised and most cases can 
be identified. However, it is less clear how effective 
contact tracing is when, as with the Ebola virus in west 
Africa and SARS in Asia and parts of Europe and North 
America, transmission becomes widespread and many 
transmission chains are unknown. Because of a dearth 
of other options, contact tracing remains the main 
control strategy in such scenarios, especially if no widely 
deployable vaccine is available. For example, when asked 
what would have been done if the recently ended Ebola 
virus outbreak in the Democratic Republic of the Congo’s 
